Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
Abstract Aims Sacubitril/valsartan (SV) reduced heart failure hospitalization and cardiovascular mortality compared with enalapril in the Prospective Comparison of ARNI with ACE‐I to Determine Impact on Global Mortality and Morbidity in Heart Failure trial. However, this trial excluded patients with...
Saved in:
Main Authors: | Seonhwa Lee, Jaewon Oh, Hyoeun Kim, Jaehyung Ha, Kyeong‐hyeon Chun, Chan Joo Lee, Sungha Park, Sang‐Hak Lee, Seok‐Min Kang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-06-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12659 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01) -
Sacubitril/valsartan on right ventricular-pulmonary artery coupling and albumin-bilirubin score in heart failure in Chinese patients with reduced ejection fraction
by: Yanan Shi, et al.
Published: (2025-01-01) -
Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01) -
Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01) -
Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)